Skip to content
naulon
Get started

No retraction, correction or concern found when last checked on Oct 21, 2026.

The Roles of Post-translational Modifications on α-Synuclein in the Pathogenesis of Parkinson’s Diseases

Jiaming Zhang, Xiaoping Li, Jia-Da Li

Frontiers in Neuroscience · 2019 · Review · CC BY

doi:10.3389/fnins.2019.00381

Abstract

Parkinson’s disease is the second most common neurodegenerative disorder. Although the pathogenesis of Parkinson’s disease is not entirely clear, the aberrant aggregation of α-synuclein has long been considered as an important risk factor. Elucidating the mechanisms that influence the aggregation of α-synuclein is essential for developing effective diagnostic, preventative and therapeutic strategy to treat this devastating disease. The aggregation of α-synuclein is influenced by several post-translational modifications. Here, we summarized the major post-translational modifications (Phosphorylation, Ubiquitination, Truncation, Nitration, O-GlcNAcylation) of α-synuclein and the effect of these modifications on α-synuclein aggregation, which may provide potential targets for future therapeutics.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Parkinson’s disease (PD), the second most common neurodegenerative disorder, manifests with resting tremor, bradykinesia, rigidity, postural instability, and gait impairment. PD is characterized by loss of dopaminergic neuronal cells in the substantia nigra pars compacta (SNpc) and cytoplasmic deposition of amyloid-like aggregates termed Lewy Bodies (LB).

The major component of LB is α-synuclein aggregates. Furthermore, duplications, triplications, or point mutations in α-synuclein also contribute to some autosomal dominant early-onset PDs and sporadic PDs. identified the α-synuclein A53T mutation in a PD patient. Several other mutations have been identified since then, such as A30P, A18T, A29S, E46K, H50Q, G51D, and A53E.

The contribution of α-synuclein in the pathogenesis of PD has been extensively studied in a variety of animal models, including mice, Drosophila, and Caenorhabditis elegans. Transgenic mice or flies overexpressing WT, A30P or A53T α-synuclein show motor deficits and neuronal inclusions. The α-synuclein aggregates in dopaminergic neurons are found in WT, A30P, or A53T human α-synuclein transgenic nematodes C. elegans. Overexpression of human α-synuclein in C. elegans causes age- and dose-dependent dopaminergic neurodegeneration.

α-Synuclein also undergoes extensive post-translational modification (PTM), which influence the aggregation and/or cytotoxicity. PTMs may mediate the environmental factors on the pathogenesis. In this review, we will summarize physiological and pathological roles of α-synuclein, emphasizing the involvement of PTMs.

Structure of α-Synuclein

In humans, α-synuclein is a member of synuclein family, which includes α-synuclein, β-synuclein, and γ-synuclein. α-Synuclein, a 140-amino acid protein, is composed of three distinct domains. The N-terminus (1–60 residues) contains four imperfect KTKEGV motif repeats. The central hydrophobic domain of α-synuclein (61–95 residues), also known as the non-amyloid component (NAC), is crucial for its aggregation. The C-terminus (96–140 residues) is enriched in acidic residues and is the major phosphorylation site.

α-Synucleins purified from bacterial or mouse tissues under denaturing conditions are ‘natively unfolded’ monomers of about 14 kDa. It may acquire α-helical secondary structure upon binding to lipid vesicles. found that endogenous α-synuclein under non-denaturing conditions form a folded tetramer and non-crosslinked monomer in all cells, plus some putative dimers in the HeLa, HEK, and red blood cells. They further showed that very few native human α-synuclein tetramers form aggregation, whereas recombinantly expressed monomers readily aggregated into amyloid-like fibrils in vitro.

Function of α-Synuclein

α-Synuclein is mainly expressed at presynaptic terminals and has been implicated in numerous cellular processes. However, the exact physiological function of α-synuclein is still unclear. Under physiological conditions, α-synuclein may be involved in the compartmentalization, storage, and recycling of neurotransmitters.

Soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins are crucial for release of neurotransmitters at the neuronal synapse, vesicle recycling, and synaptic integrity. demonstrated that α-synuclein acts as a molecular chaperone to assist the folding and refolding of SNARE proteins. α-Synuclein directly binds to the SNARE protein synaptobrevin-2 and promote the formation of SNARE-complex. Moreover, α-synuclein is also involved in the dynamics of synaptic vesicles (SVs) trafficking to control the amount of vesicles docked at the synapses during neurotransmitter release. As a result, α-synuclein null mice exhibit accelerated recovery of neurotransmitter release when presented with multiple stimuli. Depletion of α-synuclein from rodent hippocampal neurons also induces a significant loss of undocked SVs.

Aggregation of α-Synuclein

Aggregates of α-synuclein are the major component of Lewy body, the pathological marker of PD, dementia with Lewy bodies and Lewy body variant of Alzheimer’s disease. The aggregation of α-synuclein is formed in three steps. The first step is the rate-limiting step, in which the soluble unstructured monomeric species were converted into partially soluble oligomers when nucleation-dependent chain polymerization occurs. Then, the oligomers aggregate into insoluble mature fibrils. At last, the amyloid fibrillar aggregates are formed. have shown that α-synuclein filaments assembled in vitro or extracted from multiple system atrophy (MSA) brains are insoluble to detergents and partially resistant to proteinase K (PK) digestion. Variable amounts of neuritic PK-resistant α-synuclein have been detected in the striatum of all the LB disease cases. PK resistance of α-synuclein may be useful for the development of biomarkers of LB diseases.

Both fibrils and oligomers have been shown to display toxicity. showed that α-synuclein fibrils can lead to progressive motor impairment and cell death. Lots of studies have suggested that amyloids associated with neurodegenerative diseases spread in a prion-like fashion. Fibrillar α-synuclein assemblies seed the aggregation of monomeric α-synuclein in vitro and spread from one cell to another in cell cultures and animal models. Multiple lines of evidence have also suggested that oligomeric species of α-synuclein are toxic. In this review, we mainly summarized the evidence supporting the toxicity of α-synuclein oligomers in PD and possible mechanisms for this toxicity.

Toxicity of α-Synuclein

α-Synuclein aggregates may cause cytotoxicity through several pathways, such as mitochondrial dysfunction, endoplasmic reticulum (ER) stress, proteasome system dysfunction, phagocytosis and inflammatory response in microglia, membrane damage, and synaptic dysfunction.

Mitochondrial Dysfunction

The loss of dopaminergic neurons is a major pathological feature of PD patient. Dopaminergic neurons are particularly sensitive to mitochondrial dysfunction due to their high energy demands and increased oxidative stress. Both the monomer and oligomer of α-synuclein show toxicity to mitochondria. The translocase of the outer membrane (TOM) 20 receptors are important for the mitochondrial protein import. α-Synuclein can inhibit the protein import of mitochondria by binding to TOM20. The voltage-dependent anion channel (VDAC) is the major channel of the mitochondrial outer membrane, which controls most of the metabolite fluxes in and out of the mitochondria. showed that monomeric α-synuclein reversibly block VDAC in a highly voltage-dependent manner.

α-Synuclein oligomers cause mitochondria fragmentation in a dopaminergic cell line SH-SY5Y. α-Synuclein oligomers decreased the retention time of exogenously added calcium, promoted calcium-induced mitochondrial swelling and depolarization. α-Synuclein oligomers also accelerated cytochrome C release, which cause the apoptosis of dopaminergic neurons.

Endoplasmic Reticulum Stress

Endoplasmic reticulum is responsible for the synthesis, modification, and delivery of proteins to their target sites within the secretory pathway and the extracellular space. Disruption of any of these processes may cause ER stress. The folding-incompetent proteins can cause ER stress and an ER stress response, called unfolded protein response (UPR). UPR is the biochemical basis for many ER storage diseases. showed that α-synuclein oligomers induced ER stress in SH-SY5Y cells. found that accumulation of the toxic α-synuclein oligomers are temporally and spatially linked to the induction of chronic ER stress in the α-synuclein transgenic mice.

Proteasome System Dysfunction

Ubiquitin proteasome system is a highly regulated mechanism of intracellular protein degradation and turnover. PD patients have a vulnerable proteasomal function in the substantia nigra, which may be due to the inhibition of α-synuclein oligomers on the proteasomal system. Indeed, α-synuclein is co-localized with ubiquitin and 20S proteasomal components in Lewy bodies. The α-synuclein oligomers may directly bind to the 20S proteasome. Binding of α-synuclein oligomers to the proteasome inhibits the chymotrypsin-like proteasomal activity of the 20S proteolytic particle. Interestingly, A53T α-synuclein oligomers impaired the proteasomal activity in PC12 cells, which can be reversed by Congo Red, an inhibitor of α-synuclein oligomerization.

Phagocytosis and Inflammatory Response in Microglia

Microglia are the resident macrophage cells in the central nervous system (CNS), involved in chemotaxis, phagocytosis, and secretion of a variety of cytokines and proteases. Microglia have a close relationship with the pathogenesis of PD. found that microglial phagocytosis is enhanced by extracellular monomeric α-synuclein but inhibited by the aggregated α-synuclein. The inflammatory response in microglia is activated by Toll-like receptor 2 (TLR2). showed that extracellular α-synuclein released from neuronal cells is an endogenous agonist for TLR2.

Membrane Damage

The cell membrane is an important barrier to prevent extracellular substances from entering the cell, which ensures the relative stability of the intracellular environment and enables various biochemical reactions to run in an orderly manner. Membrane integrity is essential for the basic function of all cell types. Dysfunctional membranes can also lead to abnormal calcium homeostasis. α-Synuclein has been shown to undergo accelerated aggregation at membrane surfaces when incubated with synthetic or natural phospholipid vesicles or supported lipid bilayers, presumably because the two dimensional surface of the membrane increases the probability of molecular interactions needed for oligomerization. showed some types of α-synuclein oligomers induced cell death via disruption of cellular calcium influx by a presumably pore-forming mechanism. further confirmed that α-synuclein interacts with membranes to affect Ca2+ signaling in a structure-specific manner and the oligomeric β-sheet-rich α-synuclein species ultimately leads to Ca2+ dysregulation.

Several approaches have been developed to alleviate the α-synuclein-induced membrane damage. Endosulfine-α, which can bind specifically to membrane-associated α-synuclein, alleviates dopaminergic cell death by interfering with the formation of neurotoxic α-synuclein oligomers at the membrane surface. A novel compound NPT100-18A, which can displace α-synuclein from the membrane, can also reduce a-synuclein toxicity.

Synaptic Dysfunction

Synaptic dysfunction is an early pathological feature of PD. SNARE complex is required for SV fusion. α-Synuclein oligomers prevent the formation of the SNARE complex by binding to synaptobrevin.

Axonal transport, which relies on the microtubule (MT) network, is fundamental for the maintenance of neuronal homeostasis. showed that α-synuclein oligomers significantly inhibited MT assembly. 3,4-Dihydroxyphenylacetaldehyde (DOPAL) is a catabolite generated from dopamine by monoamine oxidase. It has been shown that DOPAL can cause α-synuclein oligomerization in vitro and in cell models. showed that this kind of α-synuclein-DOPAL oligomers can permeabilize cholesterol-containing lipid membranes mimicking SVs in vitro, which suggests that the synergistic effect of α-synuclein and DOPAL accumulation in DA neurons may lead to the formation of oligomers, negatively impacting the structure and function of SVs.

Vesicles for synaptic release are produced by the Golgi apparatus. The dysfunction of Golgi can lead to abnormity of synaptic function. showed that over-expression of α-synuclein in COS-7 cells caused Golgi fragmentation. As mentioned previously, pore-like oligomers of α-synuclein could also rupture SVs, leading to decreased neurotransmitter release, as well as permeabilization of cell membranes, which could result in Ca2+ influx and excitotoxicity.

Post-Translational Modifications of α-Synuclein

α-Synuclein is subjected to extensive post-transcriptional modifications (PTMs), including phosphorylation, ubiquitination, nitration, truncation, and O-GlcNAcylation. PTMs of α-synuclein may influence its toxicity and aggregation.

Phosphorylation

α-Synuclein within LB can be phosphorylated at serine 129 and 87 (S129-P, S87-P). S129-P has emerged as a defining hallmark of PD and related synucleinopathies. showed that α-synuclein is also phosphorylated at tyrosine 125, 133, and 136 (Y125-P, Y133-P, and Y136-P). The kinases that mediate phosphorylation at Y125 of α-synuclein are still unknown. have developed a semi-synthetic strategy that enables the site-specific introduction of single phosphorylation at Y125. They showed that phosphorylation at Y125 does not affect the fibrillization of α-synuclein. The impact of the phosphorylation at tyrosine 133 and 135 on α-synuclein aggregation is still unknown.

A number of kinases have been shown to phosphorylate α-synuclein at S129 in vitro, including casein kinase I (CKI), casein kinase II (CKII), the G protein-coupled receptor kinases (GRK), LRRK2, and polo-like kinases (PLK).

showed that phosphorylation of S129 in α-synuclein by CKII promotes in vitro fibrillation. indicated that phosphorylation at S-129 by CKII promotes the formation of cytoplasmic inclusions in some cell culture models.

Phosphorylation of α-synuclein at S-129 by GRK2 was reported to be toxic. have studied the phosphorylation of α-synuclein in Drosophila. They showed that co-expression of Drosophila GRK2 with α-synuclein enhances the formation of α-synuclein oligomers and accelerates neuronal loss, as compared to the Drosophila expressing α-synuclein alone.

α-Synuclein phosphorylation at S129 is largely reduced in PLK2-/- transgenic mice, supporting the involvement of PLK in α-synuclein phosphorylation in vivo. PLK2-induced phosphorylation has no effect on the aggregation of α-synuclein. Nevertheless, showed that PLK2 binds directly to α-synuclein in an ATP-dependent manner and regulates α-synuclein selective clearance via the lysosome–autophagic degradation pathway, which suggests a neuroprotective role of PLK2 against PD pathology.

Ubiquitination and Sumoylation

The core of LBs is immunoreactive for both α-synuclein and ubiquitin proteins and is surrounded by a rim of α-synuclein. However, the major α-synuclein species in LBs is mono-, di-, and tri-ubiquitinated, suggesting the involvement of ubiquitination in the pathophysiologic properties of α-synuclein. The ubiquitination of α-synuclein is correlated with three E3 ubiquitin-protein ligases: C-terminal U-box domain of co-chaperone Hsp70-interacting protein (CHIP), seven in absentia homolog (SIAH) and neuronal precursor cell-expressed, developmentally down-regulated gene 4 (Nedd4).

The mammalian homologs of Drosophila seven in absentia (SIAH-1 and SIAH-2) gene have been characterized as a family of RING-type E3 ligases. Both in vivo and in vitro data showed that ubiquitination of α-synuclein by SIAH promotes the formation of inclusions. showed that ubiquitination of α-synuclein in vitro by SIAH promotes the formation of higher molecular weight α-synuclein. They then used electron microscopy to show that α-synuclein ubiquitinated by SIAH formed more aggregates. also showed that SIAH-1 or SIAH-2-mediated ubiquitination enhances the aggregation of α-synuclein and formation of α-synuclein-positive inclusion in PC12 cells and SH-SY5Y human neuroblastoma.

CHIP is a multidomain chaperone, utilizing both a tetratricopeptide/Hsp70 binding domain and a U-box/ubiquitin ligase domain to recognize misfolded proteins. CHIP is able to mono- and poly-ubiquitinate α-synuclein. showed that CHIP colocalizes with α-synuclein in Lewy bodies and also in a cell culture model of α-synuclein inclusions. Overexpression of CHIP inhibits α-synuclein aggregation and increases α-synuclein degradation in cell culture. Interestingly, they also indicated that CHIP can regulate α-synuclein degradation both via the proteasomal degradation pathway and the lysosomal degradation pathway. A study from showed that CHIP selectively reduced α-synuclein oligomerization and toxicity in a tetratricopeptide domain-dependent, U-box independent manner by specifically degrading toxic α-synuclein oligomers.

Nedd4 is a HECT-domain E3 that functions at the plasma membrane in the turnover of a number of membrane-associated proteins. showed that Nedd4 can act as an E3 for α-synuclein. They demonstrated that Nedd4 directly binds to α-synuclein in brain and cell extracts and promotes the degradation of endogenous α-synuclein by lysosomes. They further found that Nedd4-mediated degradation protects against α-synuclein-induced toxicity in the Drosophila and rodent models of Parkinson’s disease. Nedd4-1-linked Lys-63 ubiquitination was demonstrated to specify the fate of extrinsic and de novo synthesized α-synuclein by facilitating their targeting to endosomes. In yeast ubiquitin ligase, the Nedd4 ortholog Rsp5 is a key enzyme involved in the degradation of abnormal or unfavorable proteins. have isolated novel hyperactive forms of Rsp5 that alleviate α-synuclein toxicity, by enhancing the clearance of α-synuclein, including the processes of interaction, ubiquitination, and degradation.

The site-specific effects of ubiquitination on aggregation and clearance have been studied using a semi-synthetic strategy. Monomeric ubiquitination of α-synuclein at K6 was shown to resist fibril formation when compared to unmodified protein; Ubiquitination of α-synuclein at K10 and K23 readily form fibrils; Ubiquitination of α-synuclein at K6, K12, and K21 moderately inhibit the formation of fibrils; Ubiquitination of α-synuclein at K32, K34, K43, and K96 displayed no fibril formation, suggesting a strong inhibitory effect. have incorporated K48-linked di- or tetra-Ub chains onto the side chain of Lys12 of α-synuclein and demonstrated that the length of the Ub chain plays an important role in regulating α-synuclein fibril formation and clearance.

α-Synuclein is also conjugated to small ubiquitin-like modifier (SUMO) at lysines. demonstrated that α-synuclein is SUMOylated by PIAS2, and SUMOylated α-synuclein and PIAS2 are markedly elevated in the substantia nigra of PD brains. Further, Lewy bodies are positive for both SUMO1 and PIAS2. They found that SUMOylation increases α-synuclein aggregation by two self-reinforcing mechanisms. First, SUMOylation by PIAS2 directly promotes the aggregation of α-synuclein. Second, SUMOylation impairs α-synuclein ubiquitination and prevents α-synuclein degradation. Therefore, SUMOylation blockers may provide a strategy to prevent intracellular α-synuclein aggregation. However, showed that sumoylation inhibits α-synuclein aggregation and toxicity. In vitro study demonstrated that SUMOylation at K102 of α-synuclein results in more pronounced inhibition of aggregation than the corresponding modification at K96.

Truncation

Besides full-length α-synuclein, there exist small amounts of various truncated species with apparent molecular masses of 10–15 kDa in the LBs. It is estimated that about 15% α-synuclein in LBs is truncated. And the C-terminally truncated α-synuclein may act as effective seeds to accelerate the aggregation of the full-length protein.

The carboxyl-terminal-truncated α-synuclein produced by aberrant proteolysis, is found in association with α-synuclein aggregates. investigated the effects of truncation by generating both transgenic Drosophila and transgenic mice expressing human α-synuclein. They found that the truncated form of α-synuclein (1–120) increased accumulation of high molecular weight α-synuclein species, and enhanced neurotoxicity in vivo. They showed that the striatal dopamine levels are reduced and the transgenic mice showed a progressive reduction in spontaneous locomotion and an increased response to amphetamine. used recombinant proteins and showed that the fragments (1–110; 1–119; 110–140) promoting nucleation seed the aggregation of full-length α-synuclein. also showed that the truncated α-synuclein variants, 1–89, 1–102, 1–110, 1–120, and 1–130 aggregated more rapidly than the full-length protein.

Several enzymes have been implicated in the truncation of α-synuclein, including calpain I, Neurosin, Cathepsin D, and Matrix metalloproteinase 3.

Since α-synuclein is predominantly localized to the pre-synaptic terminal, it may be a substrate for soluble or membrane-associated proteases such as the calcium-activated neutral protease calpain I. demonstrated that Calpain I cleaves wild-type α-synuclein predominantly after amino acid 57 and within the NAC region (73, 74, and 83). Calpain-mediated processing of soluble α-synuclein inhibits fibrillization, while processing of fibrillar α-synuclein promotes further aggregation.

Neurosin, a serine protease predominantly expressed in the CNS, is presumed to play an important role in the degradation of α-synuclein. Neurosin cleaves α-synuclein after amino acid 80 and 97. Cleavage of α-synuclein after 80 by neurosin may inhibit the polymerization; however, the fragment cleaved after 97 has a stronger propensity to polymerize than non-processed α-synuclein.

Nitration

Oxidative injury has been implicated in the pathogenesis of PD. The action of oxygen and nitric oxide and their products, especially peroxynitrite, leads to the nitration of tyrosine residues in proteins. first showed that a-synuclein is nitrated when present in the major filamentous and in the insoluble fractions of affected brain regions of synucleinopathies. All four tyrosine residues in α-synuclein (Y39, Y125, Y133, and Y136) are susceptible to nitration.

showed that nitration of Y-39 accelerates the oligomerization of α-synuclein, and a mutation in this residue leads to high levels of fibrilization.

showed that monomeric or dimeric forms of nitrated α-synuclein accelerate the fibril formation and seed the fibrillation of non-modified α-synuclein. On the other hand, nitrated α-synuclein oligomers inhibit the fibril formation.

Through site-specific incorporation of 3-nitrotyrosine at different regions of α-synuclein, indicated that different site-specifically nitrated α-synuclein species exhibit distinct aggregation properties. They further showed that intermolecular interactions between the N- and C-terminal regions of α-synuclein play critical roles in mediating nitration-induced α-synuclein oligomerization.

O-GlcNAcylation

O-GlcNAcylation is a dynamic biochemical process, in which N-acetylglucosamine (GlcNAc) from uridine 5′-diphospho-N-acetylglucosamine (UDP-GlcNAc) is transferred to the serine and threonine residues of proteins by O-GlcNAc transferase (OGT) and removed by O-GlcNAcase (OGA). More than 1,000 proteins can be modified by O-GlcNAc, including molecular chaperones, transcription factors, RNA polymerase II, nucleoporin, RNA binding proteins, kinases, and cytoskeletal proteins. O-GlcNAcylation has identified threonine (T) residue 33, 34, 54, 59, 64, 72, 75, 81, and 87 of α-synuclein isolated from mouse and human samples.

To understand the effect of O-GlcNAcylation on the aggregation of α-synuclein, synthesized a peptide of α-synuclein comprising residues 68–77, in which the T72 is O-GlcNAcylated. As compared with the unmodified peptide, the O-GlcNAcylated peptide inhibits full-length α-synuclein fibrillization. They further synthesized a full-length α-synuclein, with O-GlcNAcylation at T72. O-GlcNAcylation at T72 completely blocks the formation of both fiber and oligomer aggregates in vitro. They synthesized a full-length α-synuclein with O-GlcNAcylation at S87, which still aggregates but with slower kinetics than the unmodified protein. Recently, showed that several of the O-GlcNAc sites inhibit the toxicity of extracellular α-synuclein fibers that are likely culprits in the spread of PD. They also demonstrated that O-GlcNAcylation can inhibit the aggregation of an aggressive mutant of α-synuclein.

To study the functional consequences of enzymatic O-GlcNAcylation of α-synuclein, we co-expressed a shorter form of OGT (sOGT) and α-synuclein in bacteria and got enzymatically O-GlcNAcylated α-synuclein. The enzymatic O-GlcNAcylation also significantly blocked α-synuclein aggregation.

Conclusion and Perspective

In this review, we have summarized the major PTMs of α-synuclein (Figure 1). Since the presence of PTMs in α-synuclein is able to influence its aggregation and toxicity (Table 1), targeting PTMs may be used to develop novel therapeutic approaches for PD. However, it should be noted that most of the effect of PTMs on the α-synuclein aggregation are carried out in vitro; the in vivo effect is still elusive. Furthermore, α-synuclein may have multiple different PTMs at the same time in vivo; however, the current researches regarding PTMs of α-synuclein are studied individually. The interaction of PTMs of α-synuclein has been widely studied. Phosphorylated α-synuclein has been reported to be one of the target proteins for ubiquitination in synucleinopathies., for the first time, demonstrated an interplay between α-synuclein sumoylation and phosphorylation to control protein turnover. They showed that sumoylation exhibits a protective role against α-synuclein toxicity and inclusion formation in yeast cells. There is a complex and dynamic interplay between O-GlcNAcylation and phosphorylation. The interplay between α-synuclein O-GlcNAcylation and phosphorylation is still unknown. As mentioned before, neurosin is one enzyme that mediates the truncation of α-synuclein. showed that phosphorylated α-synuclein was more resistant to degradation by neurosin than non-phosphorylated α-synuclein. A reciprocal reaction may also occur between other PTMs, which still need further study. Third, it is interesting that, in some cases, the same modification may have a different effect. For instance, phosphorylation at S129 by CKII may promote aggregation, but phosphorylation at S129 by PLK2 promotes degradation. More studies are required to understand the underlying mechanisms for the discrepancy. Lastly, although it is well known that PTMs are regulated by the environmental stimuli, few studies have attempted to use PTMs to link environmental factors and α-synuclein toxicity. Thus, future studies on the PTMs of α-synuclein in vivo will help to address these concerns, and improve our understanding surrounding the role of the gene-environment interaction in PD pathogenesis.

Author Contributions

All authors participated in designing the concept of this manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 156

  1. 1.

    Abeywardana T. Lin Y. H. Rott R. Engelender S. Pratt M. R. (2013 ). Site-specific differences in proteasome-dependent degradation of monoubiquitinated alpha-synuclein. Chem. Biol. 20 1207–1213.

    Not in our library10.1016/j.chembiol.2013.09.009

  2. 2.

    Abeywardana T. Pratt M. R. (2015 ). Extent of inhibition of alpha-synuclein aggregation in vitro by SUMOylation is conjugation site- and SUMO isoform-selective. Biochemistry 54 959–961.

    Not in our library10.1021/bi501512m

  3. 3.

    Adamczyk A. Solecka J. Strosznajder J. B. (2005 ). Expression of alpha-synuclein in different brain parts of adult and aged rats. J. Physiol. Pharmacol. 56 29–37.

    Not in our library

  4. 4.

    Ahn S. Kim J. Lucaveche C. L. Reedy M. C. Luttrell L. M. Lefkowitz R. J. (2002 ). Src-dependent tyrosine phosphorylation regulates dynamin self-assembly and ligand-induced endocytosis of the epidermal growth factor receptor. J. Biol. Chem. 277 26642–26651.

    Not in our library10.1074/jbc.m201499200

  5. 5.

    Alfaro J. F. Gong C. X. Monroe M. E. Aldrich J. T. Clauss T. R. Purvine S. O. (2012 ). Tandem mass spectrometry identifies many mouse brain O-GlcNAcylated proteins including EGF domain-specific O-GlcNAc transferase targets. Proc. Natl. Acad. Sci. U.S.A. 109 7280–7285.

    Not in our library10.1073/pnas.1200425109

  6. 6.

    Allen Reish H. E. Standaert D. G. (2015 ). Role of alpha-synuclein in inducing innate and adaptive immunity in Parkinson disease. J. Parkinsons Dis. 5 1–19.

    Not in our library10.3233/jpd-140491

  7. 7.

    Anderson J. P. Walker D. E. Goldstein J. M. de Laat R. Banducci K. Caccavello R. J. (2006 ). Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 281 29739–29752.

    Not in our library10.1074/jbc.m600933200

  8. 8.
    Ca2+ is a key factor in α-synuclein-induced neurotoxicity · 2016
    No notice
  9. 9.

    Auluck P. K. Caraveo G. Lindquist S. (2010 ). alpha-Synuclein: membrane interactions and toxicity in Parkinson’s disease. Annu. Rev. Cell Dev. Biol. 26 211–233.

    Not in our library10.1146/annurev.cellbio.042308.113313

  10. 10.

    Baba M. Nakajo S. Tu P. H. Tomita T. Nakaya K. Lee V. M. (1998 ). Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy bodies. Am. J. Pathol. 152 879–884.

    Not in our library

  11. 11.

    Bartels T. Choi J. G. Selkoe D. J. (2011 ). alpha-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 477 107–110.

    Not in our library10.1038/nature10324

  12. 12.

    Bose A. Beal M. F. (2016 ). Mitochondrial dysfunction in Parkinson’s disease. J. Neurochem. 139(Suppl. 1), 216–231.

    Not in our library10.1111/jnc.13731

  13. 13.

    Braak H. Del Tredici K. Rub U. de Vos R. A. Jansen Steur E. N. Braak E. (2003 ). Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 24 197–211.

    Not in our library10.1016/s0197-4580(02)00065-9

  14. 14.

    Burai R. Ait-Bouziad N. Chiki A. Lashuel H. A. (2015 ). Elucidating the role of site-specific nitration of alpha-synuclein in the pathogenesis of Parkinson’s disease via protein semisynthesis and mutagenesis. J. Am. Chem. Soc. 137 5041–5052.

    Not in our library10.1021/ja5131726

  15. 15.

    Burke W. J. Kumar V. B. Pandey N. Panneton W. M. Gan Q. Franko M. W. (2008 ). Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 115 193–203.

    Not in our library10.1007/s00401-007-0303-9

  16. 16.

    Burke W. J. Li S. W. Williams E. A. Nonneman R. Zahm D. S. (2003 ). 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson’s disease pathogenesis. Brain Res. 989 205–213.

    Not in our library10.1016/s0006-8993(03)03354-7

  17. 17.

    Burre J. (2015 ). The synaptic function of alpha-synuclein. J. Parkinsons Dis. 5 699–713.

    Not in our library10.3233/jpd-150642

  18. 18.

    Burre J. Sharma M. Tsetsenis T. Buchman V. Etherton M. R. Sudhof T. C. (2010 ). Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 329 1663–1667.

    Not in our library10.1126/science.1195227

  19. 19.

    Cabin D. E. Shimazu K. Murphy D. Cole N. B. Gottschalk W. McIlwain K. L. (2002 ). Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J. Neurosci. 22 8797–8807.

    Not in our library10.1523/jneurosci.22-20-08797.2002

  20. 20.

    Campbell B. C. McLean C. A. Culvenor J. G. Gai W. P. Blumbergs P. C. Jakala P. (2001 ). The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson’s disease. J. Neurochem. 76 87–96.

    Not in our library10.1046/j.1471-4159.2001.00021.x

  21. 21.

    Cao S. Gelwix C. C. Caldwell K. A. Caldwell G. A. (2005 ). Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. J. Neurosci. 25 3801–3812.

    Not in our library10.1523/jneurosci.5157-04.2005

  22. 22.

    Castillo-Carranza D. L. Zhang Y. Guerrero-Munoz M. J. Kayed R. Rincon-Limas D. E. Fernandez-Funez P. (2012 ). Differential activation of the ER stress factor XBP1 by oligomeric assemblies. Neurochem. Res. 37 1707–1717.

    Not in our library10.1007/s11064-012-0780-7

  23. 23.

    Choi B. K. Choi M. G. Kim J. Y. Yang Y. Lai Y. Kweon D. H. (2013 ). Large alpha-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. Proc. Natl. Acad. Sci. U.S.A. 110 4087–4092.

    Not in our library10.1073/pnas.1218424110

  24. 24.

    Choi D. H. Kim Y. J. Kim Y. G. Joh T. H. Beal M. F. Kim Y. S. (2011 ). Role of matrix metalloproteinase 3-mediated alpha-synuclein cleavage in dopaminergic cell death. J. Biol. Chem. 286 14168–14177.

    Not in our library10.1074/jbc.m111.222430

  25. 25.

    Colla E. Coune P. Liu Y. Pletnikova O. Troncoso J. C. Iwatsubo T. (2012 ). Endoplasmic reticulum stress is important for the manifestations of alpha-synucleinopathy in vivo. J. Neurosci. 32 3306–3320.

    Not in our library10.1523/jneurosci.5367-11.2012

  26. 26.

    Crowther R. A. Jakes R. Spillantini M. G. Goedert M. (1998 ). Synthetic filaments assembled from C-terminally truncated alpha-synuclein. FEBS Lett. 436 309–312.

    Not in our library10.1016/s0014-5793(98)01146-6

  27. 27.

    Danielson S. R. Held J. M. Schilling B. Oo M. Gibson B. W. Andersen J. K. (2009 ). Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative model of Parkinson’s disease. Anal. Chem. 81 7823–7828.

    Not in our library10.1021/ac901176t

  28. 28.

    Danzer K. M. Haasen D. Karow A. R. Moussaud S. Habeck M. Giese A. (2007 ). Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 27 9220–9232.

    Not in our library10.1523/jneurosci.2617-07.2007

  29. 29.

    Davidson W. S. Jonas A. Clayton D. F. George J. M. (1998 ). Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273 9443–9449.

    Not in our library10.1074/jbc.273.16.9443

  30. 30.
    Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's disease · 2014
    Not checked
  31. 31.

    Demand J. Alberti S. Patterson C. Hohfeld J. (2001 ). Cooperation of a ubiquitin domain protein and an E3 ubiquitin ligase during chaperone/proteasome coupling. Curr. Biol. 11 1569–1577.

    Not in our library10.1016/s0960-9822(01)00487-0

  32. 32.

    Desplats P. Lee H. J. Bae E. J. Patrick C. Rockenstein E. Crews L. (2009 ). Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl. Acad. Sci. U.S.A. 106 13010–13015.

    Not in our library10.1073/pnas.0903691106

  33. 33.

    Di Maio R. Barrett P. J. Hoffman E. K. Barrett C. W. Zharikov A. Borah A. (2016 ). alpha-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease. Sci. Transl. Med. 8:342ra78.

    Not in our library10.1126/scitranslmed.aaf3634

  34. 34.

    Eliezer D. Kutluay E. Bussell R. Jr. Browne G. (2001 ). Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol. Biol. 307 1061–1073.

    Not in our library10.1006/jmbi.2001.4538

  35. 35.

    Ellis C. E. Schwartzberg P. L. Grider T. L. Fink D. W. Nussbaum R. L. (2001 ). alpha-synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases. J. Biol. Chem. 276 3879–3884.

    Not in our library10.1074/jbc.m010316200

  36. 36.

    Emmanouilidou E. Stefanis L. Vekrellis K. (2010 ). Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol. Aging 31 953–968.

    Not in our library10.1016/j.neurobiolaging.2008.07.008

  37. 37.

    Farrer M. Kachergus J. Forno L. Lincoln S. Wang D. S. Hulihan M. (2004 ). Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 55 174–179.

    Not in our library10.1002/ana.10846

  38. 38.

    Feany M. B. Bender W. W. (2000 ). A Drosophila model of Parkinson’s disease. Nature 404 394–398.

    Not in our library10.1038/35006074

  39. 39.
    Microglia Response During Parkinson’s Disease: Alpha-Synuclein Intervention · 2018
    No notice
  40. 40.

    Forno L. S. (1996 ). Neuropathology of Parkinson’s disease. J. Neuropathol. Exp. Neurol. 55 259–272.

    Not in our library10.1097/00005072-199603000-00001

  41. 41.

    Fujiwara H. Hasegawa M. Dohmae N. Kawashima A. Masliah E. Goldberg M. S. (2002 ). alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4 160–164.

    Not in our library10.1038/ncb748

  42. 42.

    Gerst J. E. (1999 ). SNAREs and SNARE regulators in membrane fusion and exocytosis. Cell. Mol. Life Sci. 55 707–734.

    Not in our library10.1007/s000180050328

  43. 43.

    Giasson B. I. Duda J. E. Murray I. V. Chen Q. Souza J. M. Hurtig H. I. (2000 ). Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290 985–989.

    Not in our library10.1126/science.290.5493.985

  44. 44.

    Giasson B. I. Murray I. V. Trojanowski J. Q. Lee V. M. (2001 ). A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 276 2380–2386.

    Not in our library10.1074/jbc.m008919200

  45. 45.

    Goda Y. (1997 ). SNAREs and regulated vesicle exocytosis. Proc. Natl. Acad. Sci. U.S.A. 94 769–772.

    Not in our library10.1073/pnas.94.3.769

  46. 46.

    Golbe L. I. Di Iorio G. Bonavita V. Miller D. C. Duvoisin R. C. (1990 ). A large kindred with autosomal dominant Parkinson’s disease. Ann. Neurol. 27 276–282.

    Not in our library10.1002/ana.410270309

  47. 47.

    Goldstein A. Y. Wang X. Schwarz T. L. (2008 ). Axonal transport and the delivery of pre-synaptic components. Curr. Opin. Neurobiol. 18 495–503.

    Not in our library10.1016/j.conb.2008.10.003

  48. 48.

    Goldstein D. S. Sullivan P. Holmes C. Kopin I. J. Basile M. J. Mash D. C. (2011 ). Catechols in post-mortem brain of patients with Parkinson disease. Eur. J. Neurol. 18 703–710.

    Not in our library10.1111/j.1468-1331.2010.03246.x

  49. 49.

    Gomez-Tortosa E. Newell K. Irizarry M. C. Sanders J. L. Hyman B. T. (2000 ). alpha-Synuclein immunoreactivity in dementia with Lewy bodies: morphological staging and comparison with ubiquitin immunostaining. Acta Neuropathol. 99 352–357.

    Not in our library10.1007/s004010051135

  50. 50.

    Gosavi N. Lee H. J. Lee J. S. Patel S. Lee S. J. (2002 ). Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion. J. Biol. Chem. 277 48984–48992.

    Not in our library10.1074/jbc.m208194200

  51. 51.

    Haj-Yahya M. Fauvet B. Herman-Bachinsky Y. Hejjaoui M. Bavikar S. N. Karthikeyan S. V. (2013 ). Synthetic polyubiquitinated alpha-Synuclein reveals important insights into the roles of the ubiquitin chain in regulating its pathophysiology. Proc. Natl. Acad. Sci. U.S.A. 110 17726–17731.

    Not in our library10.1073/pnas.1315654110

  52. 52.

    Hamamichi S. Rivas R. N. Knight A. L. Cao S. Caldwell K. A. Caldwell G. A. (2008 ). Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson’s disease model. Proc. Natl. Acad. Sci. U.S.A. 105 728–733.

    Not in our library10.1073/pnas.0711018105

  53. 53.

    Hampton R. Y. (2000 ). ER stress response: getting the UPR hand on misfolded proteins. Curr. Biol. 10 R518–R521.

    Not in our library10.1016/s0960-9822(00)00583-2

  54. 54.

    Hansen C. Angot E. Bergstrom A. L. Steiner J. A. Pieri L. Paul G. (2011 ). alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 121 715–725.

    Not in our library10.1172/jci43366

  55. 55.

    Haque F. Pandey A. P. Cambrea L. R. Rochet J. C. Hovis J. S. (2010 ). Adsorption of alpha-synuclein on lipid bilayers: modulating the structure and stability of protein assemblies. J. Phys. Chem. B 114 4070–4081.

    Not in our library10.1021/jp1006704

  56. 56.

    Hardiville S. Hart G. W. (2014 ). Nutrient regulation of signaling, transcription, and cell physiology by O-GlcNAcylation. Cell Metab. 20 208–213.

    Not in our library10.1016/j.cmet.2014.07.014

  57. 57.

    Harper J. D. Lieber C. M. Lansbury P. T. Jr. (1997 ). Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer’s disease amyloid-beta protein. Chem. Biol. 4 951–959.

    Not in our library10.1016/s1074-5521(97)90303-3

  58. 58.

    Hart G. W. Housley M. P. Slawson C. (2007 ). Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature 446 1017–1022.

    Not in our library10.1038/nature05815

  59. 59.

    Hasegawa M. Fujiwara H. Nonaka T. Wakabayashi K. Takahashi H. Lee V. M. (2002 ). Phosphorylated alpha-synuclein is ubiquitinated in alpha-synucleinopathy lesions. J. Biol. Chem. 277 49071–49076.

    Not in our library10.1074/jbc.m208046200

  60. 60.

    Hejjaoui M. Haj-Yahya M. Kumar K. S. Brik A. Lashuel H. A. (2011 ). Towards elucidation of the role of ubiquitination in the pathogenesis of Parkinson’s disease with semisynthetic ubiquitinated alpha-synuclein. Angew. Chem. Int. Ed. Engl. 50 405–409.

    Not in our library10.1002/anie.201005546

  61. 61.

    Hodara R. Norris E. H. Giasson B. I. Mishizen-Eberz A. J. Lynch D. R. Lee V. M. (2004 ). Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. J. Biol. Chem. 279 47746–47753.

    Not in our library10.1074/jbc.m408906200

  62. 62.

    Hoffman-Zacharska D. Koziorowski D. Ross O. A. Milewski M. Poznanski J. A. Jurek M. (2013 ). Novel A18T and pA29S substitutions in alpha-synuclein may be associated with sporadic Parkinson’s disease. Parkinsonism Relat. Disord. 19 1057–1060.

    Not in our library10.1016/j.parkreldis.2013.07.011

  63. 63.

    Hoyer W. Cherny D. Subramaniam V. Jovin T. M. (2004 ). Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Biochemistry 43 16233–16242.

    Not in our library10.1021/bi048453u

  64. 64.

    Inglis K. J. Chereau D. Brigham E. F. Chiou S. S. Schobel S. Frigon N. L. (2009 ). Polo-like kinase 2 (PLK2) phosphorylates alpha-synuclein at serine 129 in central nervous system. J. Biol. Chem. 284 2598–2602.

    Not in our library10.1074/jbc.c800206200

  65. 65.

    Iwata A. Maruyama M. Akagi T. Hashikawa T. Kanazawa I. Tsuji S. (2003 ). Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies. Hum. Mol. Genet. 12 2625–2635.

    Not in our library10.1093/hmg/ddg283

  66. 66.

    Kahle P. J. Neumann M. Ozmen L. Muller V. Jacobsen H. Schindzielorz A. (2000 ). Subcellular localization of wild-type and Parkinson’s disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J. Neurosci. 20 6365–6373.

    Not in our library10.1523/jneurosci.20-17-06365.2000

  67. 67.
    Ubiquitinylation of α-Synuclein by Carboxyl Terminus Hsp70-Interacting Protein (CHIP) Is Regulated by Bcl-2-Associated Athanogene 5 (BAG5) · 2011
    No notice
  68. 68.

    Kasai T. Tokuda T. Yamaguchi N. Watanabe Y. Kametani F. Nakagawa M. (2008 ). Cleavage of normal and pathological forms of alpha-synuclein by neurosin in vitro. Neurosci. Lett. 436 52–56.

    Not in our library10.1016/j.neulet.2008.02.057

  69. 69.

    Kim C. Ho D. H. Suk J. E. You S. Michael S. Kang J. (2013 ). Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 4:1562.

    Not in our library10.1038/ncomms2534

  70. 70.

    Kruger R. Kuhn W. Muller T. Woitalla D. Graeber M. Kosel S. (1998 ). Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat. Genet. 18 106–108.

    Not in our library10.1038/ng0298-106

  71. 71.

    Krumova P. Meulmeester E. Garrido M. Tirard M. Hsiao H. H. Bossis G. (2011 ). Sumoylation inhibits alpha-synuclein aggregation and toxicity. J. Cell Biol. 194 49–60.

    Not in our library10.1083/jcb.201010117

  72. 72.

    Kuwahara T. Koyama A. Gengyo-Ando K. Masuda M. Kowa H. Tsunoda M. (2006 ). Familial Parkinson mutant alpha-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans. J. Biol. Chem. 281 334–340.

    Not in our library10.1074/jbc.m504860200

  73. 73.

    Lambert M. P. Barlow A. K. Chromy B. A. Edwards C. Freed R. Liosatos M. (1998 ). Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U.S.A. 95 6448–6453.

    Not in our library10.1073/pnas.95.11.6448

  74. 74.

    Lashuel H. A. Overk C. R. Oueslati A. Masliah E. (2013 ). The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14 38–48.

    Not in our library10.1038/nrn3406

  75. 75.

    Lee J. T. Wheeler T. C. Li L. Chin L. S. (2008 ). Ubiquitination of alpha-synuclein by Siah-1 promotes alpha-synuclein aggregation and apoptotic cell death. Hum. Mol. Genet. 17 906–917.

    Not in our library10.1093/hmg/ddm363

  76. 76.

    Lelan F. Boyer C. Thinard R. Remy S. Usal C. Tesson L. (2011 ). Effects of human alpha-synuclein A53T-A30P mutations on SVZ and local olfactory bulb cell proliferation in a transgenic rat model of Parkinson disease. Parkinsons Dis. 2011:987084.

    Not in our library10.4061/2011/987084

  77. 77.

    Levine P. M. Galesic A. Balana A. T. Mahul-Mellier A. L. Navarro M. X. De Leon C. A. (2019 ). alpha-Synuclein O-GlcNAcylation alters aggregation and toxicity, revealing certain residues as potential inhibitors of Parkinson’s disease. Proc. Natl. Acad. Sci. U.S.A. 116 1511–1519.

    Not in our library10.1073/pnas.1808845116

  78. 78.

    Lewis Y. E. Galesic A. Levine P. M. De Leon C. A. Lamiri N. Brennan C. K. (2017 ). O-GlcNAcylation of alpha-synuclein at serine 87 reduces aggregation without affecting membrane binding. ACS Chem. Biol. 12 1020–1027.

    Not in our library10.1021/acschembio.7b00113

  79. 79.

    Liani E. Eyal A. Avraham E. Shemer R. Szargel R. Berg D. (2004 ). Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson’s disease. Proc. Natl. Acad. Sci. U.S.A. 101 5500–5505.

    Not in our library10.1073/pnas.0401081101

  80. 80.

    Lima V. A. do Nascimento L. A. Eliezer D. Follmer C. (2018 ). Role of Parkinson’s disease-linked mutations and N-terminal acetylation on the oligomerization of alpha-synuclein induced by 3,4-dihydroxyphenylacetaldehyde. ACS Chem. Neurosci. [Epub ahead of print].

    Not in our library10.1021/acschemneuro.8b00498

  81. 81.

    Lin X. Parisiadou L. Sgobio C. Liu G. Yu J. Sun L. (2012 ). Conditional expression of Parkinson’s disease-related mutant alpha-synuclein in the midbrain dopaminergic neurons causes progressive neurodegeneration and degradation of transcription factor nuclear receptor related 1. J. Neurosci. 32 9248–9264.

    Not in our library10.1523/jneurosci.1731-12.2012

  82. 82.

    Lindersson E. Beedholm R. Hojrup P. Moos T. Gai W. Hendil K. B. (2004 ). Proteasomal inhibition by alpha-synuclein filaments and oligomers. J. Biol. Chem. 279 12924–12934.

    Not in our library10.1074/jbc.m306390200

  83. 83.

    Luth E. S. Stavrovskaya I. G. Bartels T. Kristal B. S. Selkoe D. J. (2014 ). Soluble, prefibrillar alpha-synuclein oligomers promote complex I-dependent, Ca2+-induced mitochondrial dysfunction. J. Biol. Chem. 289 21490–21507.

    Not in our library10.1074/jbc.m113.545749

  84. 84.

    Maguire-Zeiss K. A. Short D. W. Federoff H. J. (2005 ). Synuclein, dopamine and oxidative stress: co-conspirators in Parkinson’s disease? Brain Res. Mol. Brain Res. 134 18–23.

    Not in our library10.1016/j.molbrainres.2004.09.014

  85. 85.

    Marotta N. P. Lin Y. H. Lewis Y. E. Ambroso M. R. Zaro B. W. Roth M. T. (2015 ). O-GlcNAc modification blocks the aggregation and toxicity of the protein alpha-synuclein associated with Parkinson’s disease. Nat. Chem. 7 913–920.

    Not in our library10.1038/nchem.2361

  86. 86.

    Masliah E. Rockenstein E. Veinbergs I. Mallory M. Hashimoto M. Takeda A. (2000 ). Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287 1265–1269.

    Not in our library10.1126/science.287.5456.1265

  87. 87.

    McNaught K. S. Belizaire R. Isacson O. Jenner P. Olanow C. W. (2003 ). Altered proteasomal function in sporadic Parkinson’s disease. Exp. Neurol. 179 38–46.

    Not in our library10.1006/exnr.2002.8050

  88. 88.

    McNaught K. S. Belizaire R. Jenner P. Olanow C. W. Isacson O. (2002 ). Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson’s disease. Neurosci. Lett. 326 155–158.

    Not in our library10.1016/s0304-3940(02)00296-3

  89. 89.

    McNaught K. S. Jenner P. (2001 ). Proteasomal function is impaired in substantia nigra in Parkinson’s disease. Neurosci. Lett. 297 191–194.

    Not in our library10.1016/s0304-3940(00)01701-8

  90. 90.

    McNaught K. S. Olanow C. W. Halliwell B. Isacson O. Jenner P. (2001 ). Failure of the ubiquitin-proteasome system in Parkinson’s disease. Nat. Rev. Neurosci. 2 589–594.

    Not in our library10.1038/35086067

  91. 91.

    Meier F. Abeywardana T. Dhall A. Marotta N. P. Varkey J. Langen R. (2012 ). Semisynthetic, site-specific ubiquitin modification of alpha-synuclein reveals differential effects on aggregation. J. Am. Chem. Soc. 134 5468–5471.

    Not in our library10.1021/ja300094r

  92. 92.

    Miake H. Mizusawa H. Iwatsubo T. Hasegawa M. (2002 ). Biochemical characterization of the core structure of alpha-synuclein filaments. J. Biol. Chem. 277 19213–19219.

    Not in our library10.1074/jbc.m110551200

  93. 93.

    Mishizen-Eberz A. J. Guttmann R. P. Giasson B. I. Day G. A. III Hodara R. Ischiropoulos H. (2003 ). Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro. J. Neurochem. 86 836–847.

    Not in our library10.1046/j.1471-4159.2003.01878.x

  94. 94.

    Mishizen-Eberz A. J. Norris E. H. Giasson B. I. Hodara R. Ischiropoulos H. Lee V. M. (2005 ). Cleavage of alpha-synuclein by calpain: potential role in degradation of fibrillized and nitrated species of alpha-synuclein. Biochemistry 44 7818–7829.

    Not in our library10.1021/bi047846q

  95. 95.

    Morris M. Knudsen G. M. Maeda S. Trinidad J. C. Ioanoviciu A. Burlingame A. L. (2015 ). Tau post-translational modifications in wild-type and human amyloid precursor protein transgenic mice. Nat. Neurosci. 18 1183–1189.

    Not in our library10.1038/nn.4067

  96. 96.

    Murata S. Minami Y. Minami M. Chiba T. Tanaka K. (2001 ). CHIP is a chaperone-dependent E3 ligase that ubiquitylates unfolded protein. EMBO Rep. 2 1133–1138.

    Not in our library10.1093/embo-reports/kve246

  97. 97.

    Murray I. V. Giasson B. I. Quinn S. M. Koppaka V. Axelsen P. H. Ischiropoulos H. (2003 ). Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42 8530–8540.

    Not in our library10.1021/bi027363r

  98. 98.

    Nakamura T. Yamashita H. Takahashi T. Nakamura S. (2001 ). Activated Fyn phosphorylates alpha-synuclein at tyrosine residue 125. Biochem. Biophys. Res. Commun. 280 1085–1092.

    Not in our library10.1006/bbrc.2000.4253

  99. 99.

    Negro A. Brunati A. M. Donella-Deana A. Massimino M. L. Pinna L. A. (2002 ). Multiple phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced aggregation. FASEB J. 16 210–212.

    Not in our library10.1096/fj.01-0517fje

  100. 100.

    Neumann M. Muller V. Kretzschmar H. A. Haass C. Kahle P. J. (2004 ). Regional distribution of proteinase K-resistant alpha-synuclein correlates with Lewy body disease stage. J. Neuropathol. Exp. Neurol. 63 1225–1235.

    Not in our library10.1093/jnen/63.12.1225

  101. 101.

    Nonaka T. Iwatsubo T. Hasegawa M. (2005 ). Ubiquitination of alpha-synuclein. Biochemistry 44 361–368.

    Not in our library10.1021/bi0485528

  102. 102.

    Okochi M. Walter J. Koyama A. Nakajo S. Baba M. Iwatsubo T. (2000 ). Constitutive phosphorylation of the Parkinson’s disease associated alpha-synuclein. J. Biol. Chem. 275 390–397.

    Not in our library10.1074/jbc.275.1.390

  103. 103.

    Oueslati A. Schneider B. L. Aebischer P. Lashuel H. A. (2013 ). Polo-like kinase 2 regulates selective autophagic alpha-synuclein clearance and suppresses its toxicity in vivo. Proc. Natl. Acad. Sci. U.S.A. 110 E3945–E3954.

    Not in our library10.1073/pnas.1309991110

  104. 104.

    Paleologou K. E. Oueslati A. Shakked G. Rospigliosi C. C. Kim H. Y. Lamberto G. R. (2010 ). Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J. Neurosci. 30 3184–3198.

    Not in our library10.1523/jneurosci.5922-09.2010

  105. 105.

    Park J. Y. Paik S. R. Jou I. Park S. M. (2008 ). Microglial phagocytosis is enhanced by monomeric alpha-synuclein, not aggregated alpha-synuclein: implications for Parkinson’s disease. Glia 56 1215–1223.

    Not in our library10.1002/glia.20691

  106. 106.

    Pasanen P. Myllykangas L. Siitonen M. Raunio A. Kaakkola S. Lyytinen J. (2014 ). Novel alpha-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson’s disease-type pathology. Neurobiol. Aging 35 2180.e1–2180.e5.

    Not in our library10.1016/j.neurobiolaging.2014.03.024

  107. 107.

    Peelaerts W. Bousset L. Van der Perren A. Moskalyuk A. Pulizzi R. Giugliano M. (2015 ). alpha-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522 340–344.

    Not in our library10.1038/nature14547

  108. 108.

    Periquet M. Fulga T. Myllykangas L. Schlossmacher M. G. Feany M. B. (2007 ). Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J. Neurosci. 27 3338–3346.

    Not in our library10.1523/jneurosci.0285-07.2007

  109. 109.
    DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function · 2017
    No notice
  110. 110.

    Plotegher N. Gratton E. Bubacco L. (2014 ). Number and Brightness analysis of alpha-synuclein oligomerization and the associated mitochondrial morphology alterations in live cells. Biochim. Biophys. Acta 1840 2014–2024.

    Not in our library10.1016/j.bbagen.2014.02.013

  111. 111.

    Polymeropoulos M. H. Lavedan C. Leroy E. Ide S. E. Dehejia A. Dutra A. (1997 ). Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276 2045–2047.

    Not in our library10.1126/science.276.5321.2045

  112. 112.

    Pronin A. N. Morris A. J. Surguchov A. Benovic J. L. (2000 ). Synucleins are a novel class of substrates for G protein-coupled receptor kinases. J. Biol. Chem. 275 26515–26522.

    Not in our library10.1074/jbc.m003542200

  113. 113.

    Prots I. Veber V. Brey S. Campioni S. Buder K. Riek R. (2013 ). alpha-Synuclein oligomers impair neuronal microtubule-kinesin interplay. J. Biol. Chem. 288 21742–21754.

    Not in our library10.1074/jbc.m113.451815

  114. 114.

    Proukakis C. Dudzik C. G. Brier T. MacKay D. S. Cooper J. M. Millhauser G. L. (2013 ). A novel alpha-synuclein missense mutation in Parkinson disease. Neurology 80 1062–1064.

    Not in our library10.1212/wnl.0b013e31828727ba

  115. 115.

    Rostovtseva T. K. Gurnev P. A. Protchenko O. Hoogerheide D. P. Yap T. L. Philpott C. C. (2015 ). alpha-synuclein shows high affinity interaction with voltage-dependent anion channel, suggesting mechanisms of mitochondrial regulation and toxicity in Parkinson disease. J. Biol. Chem. 290 18467–18477.

    Not in our library10.1074/jbc.m115.641746

  116. 116.

    Rott R. Szargel R. Haskin J. Shani V. Shainskaya A. Manov I. (2008 ). Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells. J. Biol. Chem. 283 3316–3328.

    Not in our library10.1074/jbc.m704809200

  117. 117.

    Rott R. Szargel R. Shani V. Hamza H. Savyon M. Abd Elghani F. (2017 ). SUMOylation and ubiquitination reciprocally regulate alpha-synuclein degradation and pathological aggregation. Proc. Natl. Acad. Sci. U.S.A. 114 13176–13181.

    Not in our library10.1073/pnas.1704351114

  118. 118.

    Ryan B. J. Hoek S. Fon E. A. Wade-Martins R. (2015 ). Mitochondrial dysfunction and mitophagy in Parkinson’s: from familial to sporadic disease. Trends Biochem. Sci. 40 200–210.

    Not in our library10.1016/j.tibs.2015.02.003

  119. 119.

    Sampathu D. M. Giasson B. I. Pawlyk A. C. Trojanowski J. Q. Lee V. M. (2003 ). Ubiquitination of alpha-synuclein is not required for formation of pathological inclusions in alpha-synucleinopathies. Am. J. Pathol. 163 91–100.

    Not in our library10.1016/s0002-9440(10)63633-4

  120. 120.

    Sanchez-Guajardo V. Tentillier N. Romero-Ramos M. (2015 ). The relation between alpha-synuclein and microglia in Parkinson’s disease: recent developments. Neuroscience 302 47–58.

    Not in our library10.1016/j.neuroscience.2015.02.008

  121. 121.

    Schapira A. H. Jenner P. (2011 ). Etiology and pathogenesis of Parkinson’s disease. Mov. Disord. 26 1049–1055.

    Not in our library10.1002/mds.23732

  122. 122.

    Schroder M. Kaufman R. J. (2005 ). ER stress and the unfolded protein response. Mutat. Res. 569 29–63.

    Not in our library10.1016/j.mrfmmm.2004.06.056

  123. 123.

    Schulz-Schaeffer W. J. (2010 ). The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia. Acta Neuropathol. 120 131–143.

    Not in our library10.1007/s00401-010-0711-0

  124. 124.

    Sevcsik E. Trexler A. J. Dunn J. M. Rhoades E. (2011 ). Allostery in a disordered protein: oxidative modifications to alpha-synuclein act distally to regulate membrane binding. J. Am. Chem. Soc. 133 7152–7158.

    Not in our library10.1021/ja2009554

  125. 125.

    Sevlever D. Jiang P. Yen S. H. (2008 ). Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry 47 9678–9687.

    Not in our library10.1021/bi800699v

  126. 126.

    Shahpasandzadeh H. Popova B. Kleinknecht A. Fraser P. E. Outeiro T. F. Braus G. H. (2014 ). Interplay between sumoylation and phosphorylation for protection against alpha-synuclein inclusions. J. Biol. Chem. 289 31224–31240.

    Not in our library10.1074/jbc.m114.559237

  127. 127.

    Shin Y. Klucken J. Patterson C. Hyman B. T. McLean P. J. (2005 ). The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J. Biol. Chem. 280 23727–23734.

    Not in our library10.1074/jbc.m503326200

  128. 128.

    Shulman J. M. De Jager P. L. Feany M. B. (2011 ). Parkinson’s disease: genetics and pathogenesis. Annu. Rev. Pathol. 6 193–222.

    Not in our library10.1146/annurev-pathol-011110-130242

  129. 129.

    Singleton A. Gwinn-Hardy K. Sharabi Y. Li S. T. Holmes C. Dendi R. (2004 ). Association between cardiac denervation and parkinsonism caused by alpha-synuclein gene triplication. Brain 127(Pt 4), 768–772.

    Not in our library10.1093/brain/awh081

  130. 130.

    Singleton A. B. Farrer M. Johnson J. Singleton A. Hague S. Kachergus J. (2003 ). alpha-Synuclein locus triplication causes Parkinson’s disease. Science 302:841.

    Not in our library10.1126/science.1090278

  131. 131.

    Smith W. W. Margolis R. L. Li X. Troncoso J. C. Lee M. K. Dawson V. L. (2005 ). Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J. Neurosci. 25 5544–5552.

    Not in our library10.1523/jneurosci.0482-05.2005

  132. 132.

    Spillantini M. G. Crowther R. A. Jakes R. Hasegawa M. Goedert M. (1998 ). alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. U.S.A. 95 6469–6473.

    Not in our library10.1073/pnas.95.11.6469

  133. 133.

    Spillantini M. G. Schmidt M. L. Lee V. M. Trojanowski J. Q. Jakes R. Goedert M. (1997 ). Alpha-synuclein in Lewy bodies. Nature 388 839–840.

    Not in our library10.1038/42166

  134. 134.

    Stirling D. P. Cummins K. Mishra M. Teo W. Yong V. W. Stys P. (2014 ). Toll-like receptor 2-mediated alternative activation of microglia is protective after spinal cord injury. Brain 137(Pt 3), 707–723.

    Not in our library10.1093/brain/awt341

  135. 135.

    Sugeno N. Hasegawa T. Tanaka N. Fukuda M. Wakabayashi K. Oshima R. (2014 ). Lys-63-linked ubiquitination by E3 ubiquitin ligase NEDD4-1 facilitates endosomal sequestration of internalized alpha-synuclein. J. Biol. Chem. 289 18137–18151.

    Not in our library10.1074/jbc.m113.529461

  136. 136.

    Takahashi M. Kanuka H. Fujiwara H. Koyama A. Hasegawa M. Miura M. (2003 ). Phosphorylation of alpha-synuclein characteristic of synucleinopathy lesions is recapitulated in alpha-synuclein transgenic Drosophila. Neurosci. Lett. 336 155–158.

    Not in our library10.1016/s0304-3940(02)01258-2

  137. 137.

    Tanaka K. Chiba T. (1998 ). The proteasome: a protein-destroying machine. Genes Cells 3 499–510.

    Not in our library10.1046/j.1365-2443.1998.00207.x

  138. 138.

    Tetzlaff J. E. Putcha P. Outeiro T. F. Ivanov A. Berezovska O. Hyman B. T. (2008 ). CHIP targets toxic alpha-Synuclein oligomers for degradation. J. Biol. Chem. 283 17962–17968.

    Not in our library10.1074/jbc.m802283200

  139. 139.

    Tofaris G. K. Garcia Reitbock P. Humby T. Lambourne S. L. O’Connell M. Ghetti B. (2006 ). Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders. J. Neurosci. 26 3942–3950.

    Not in our library10.1523/jneurosci.4965-05.2006

  140. 140.

    Tofaris G. K. Kim H. T. Hourez R. Jung J. W. Kim K. P. Goldberg A. L. (2011 ). Ubiquitin ligase NEDD4 promotes alpha-synuclein degradation by the endosomal-lysosomal pathway. Proc. Natl. Acad. Sci. U.S.A. 108 17004–17009.

    Not in our library10.1073/pnas.1109356108

  141. 141.

    Tofaris G. K. Razzaq A. Ghetti B. Lilley K. S. Spillantini M. G. (2003 ). Ubiquitination of alpha-synuclein in Lewy bodies is a pathological event not associated with impairment of proteasome function. J. Biol. Chem. 278 44405–44411.

    Not in our library10.1074/jbc.m308041200

  142. 142.

    Tysnes O. B. Storstein A. (2017 ). Epidemiology of Parkinson’s disease. J. Neural Transm. 124 901–905.

    Not in our library10.1007/s00702-017-1686-y

  143. 143.

    Uversky V. N. Eliezer D. (2009 ). Biophysics of Parkinson’s disease: structure and aggregation of alpha-synuclein. Curr. Protein Pept. Sci. 10 483–499.

    Not in our library10.2174/138920309789351921

  144. 144.

    van der Putten H. Wiederhold K. H. Probst A. Barbieri S. Mistl C. Danner S. (2000 ). Neuropathology in mice expressing human alpha-synuclein. J. Neurosci. 20 6021–6029.

    Not in our library10.1523/jneurosci.20-16-06021.2000

  145. 145.

    Walsh D. M. Lomakin A. Benedek G. B. Condron M. M. Teplow D. B. (1997 ). Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J. Biol. Chem. 272 22364–22372.

    Not in our library10.1074/jbc.272.35.22364

  146. 146.

    Wang S. Yang F. Petyuk V. A. Shukla A. K. Monroe M. E. Gritsenko M. A. (2017 ). Quantitative proteomics identifies altered O-GlcNAcylation of structural, synaptic and memory-associated proteins in Alzheimer’s disease. J. Pathol. 243 78–88.

    Not in our library10.1002/path.4929

  147. 147.

    Wang Z. Park K. Comer F. Hsieh-Wilson L. C. Saudek C. D. Hart G. W. (2009 ). Site-specific GlcNAcylation of human erythrocyte proteins: potential biomarker(s) for diabetes. Diabetes 58 309–317.

    Not in our library10.2337/db08-0994

  148. 148.

    Wang Z. Udeshi N. D. O’Malley M. Shabanowitz J. Hunt D. F. Hart G. W. (2010 ). Enrichment and site mapping of O-linked N-acetylglucosamine by a combination of chemical/enzymatic tagging, photochemical cleavage, and electron transfer dissociation mass spectrometry. Mol. Cell. Proteomics 9 153–160.

    Not in our library10.1074/mcp.m900268-mcp200

  149. 149.

    Weinreb P. H. Zhen W. Poon A. W. Conway K. A. Lansbury P. T. Jr. (1996 ). NACP, a protein implicated in Alzheimer’s disease and learning, is natively unfolded. Biochemistry 35 13709–13715.

    Not in our library10.1021/bi961799n

  150. 150.

    Wheeler T. C. Chin L. S. Li Y. Roudabush F. L. Li L. (2002 ). Regulation of synaptophysin degradation by mammalian homologues of seven in absentia. J. Biol. Chem. 277 10273–10282.

    Not in our library10.1074/jbc.m107857200

  151. 151.

    Wijayanti I. Watanabe D. Oshiro S. Takagi H. (2015 ). Isolation and functional analysis of yeast ubiquitin ligase Rsp5 variants that alleviate the toxicity of human alpha-synuclein. J. Biochem. 157 251–260.

    Not in our library10.1093/jb/mvu069

  152. 152.

    Wood S. J. Wypych J. Steavenson S. Louis J. C. Citron M. Biere A. L. (1999 ). alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson’s disease. J. Biol. Chem. 274 19509–19512.

    Not in our library10.1074/jbc.274.28.19509

  153. 153.

    Wrasidlo W. Tsigelny I. F. Price D. L. Dutta G. Rockenstein E. Schwarz T. C. (2016 ). A de novo compound targeting alpha-synuclein improves deficits in models of Parkinson’s disease. Brain 139(Pt 12), 3217–3236.

    Not in our library10.1093/brain/aww238

  154. 154.

    Ysselstein D. Dehay B. Costantino I. M. McCabe G. P. Frosch M. P. George J. M. (2017 ). Endosulfine-alpha inhibits membrane-induced alpha-synuclein aggregation and protects against alpha-synuclein neurotoxicity. Acta Neuropathol. Commun. 5:3.

    Not in our library10.1186/s40478-016-0403-7

  155. 155.

    Zarranz J. J. Alegre J. Gomez-Esteban J. C. Lezcano E. Ros R. Ampuero I. (2004 ). The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55 164–173.

    Not in our library10.1002/ana.10795

  156. 156.

    Zhang J. Lei H. Chen Y. Ma Y. T. Jiang F. Tan J. (2017 ). Enzymatic O-GlcNAcylation of alpha-synuclein reduces aggregation and increases SDS-resistant soluble oligomers. Neurosci. Lett. 655 90–94.

    Not in our library10.1016/j.neulet.2017.06.034

Cited by papers we hold 7

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.